Also of interest is that blocking the Akt/mTOR signaling pathway by inhibitors significantly enhances the sensitivity of HCC cells to sorafenib, providing a potential combination therapeutic strategy for HCC [39]. This evidence concerns the gene AKT1 and hepatocellular carcinoma.